The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
13 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $9,220,605 in first-year total cost, median $581,087.
Most frequent study sections
- Cancer Prevention Study Section[CPSS]6
- Translational Immuno-oncology Study Section[TIO]4
- Special Emphasis Panel[ZRG1 CDPT-Z (08)]1
- Special Emphasis Panel[ZRG1 MCTC-S (01)]1
- Therapeutic Immune Regulation Study Section[TIR]1
Most frequent institutions
- UNIVERSITY OF MICHIGAN AT ANN ARBOR2
- UNIVERSITY OF TX MD ANDERSON CAN CTR2
- WEILL MEDICAL COLL OF CORNELL UNIV2
- UNIVERSITY OF ALABAMA AT BIRMINGHAM1
- UNIVERSITY OF CALIFORNIA BERKELEY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Understanding and Harnessing Microbial Reprogramming to Combat Carcinogenic Colibactin in Colorectal Cancer1R01CA303150-01 | LI, JIAHESHAH, YATRIK M | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $2,864,671 | CPSS |
| 2025 | Targeting a human gut bacterial genotoxin via engineered commensal bacteria1R01CA299955-01 | LI, JIAHEYILMAZ, OMER | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $627,422 | CPSS |
| 2025 | Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy1R01CA305986-01 | JIANG, WENKIM, BETTY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $616,715 | ZRG1 |
| 2025 | The role of microbiota amino acid metabolism in cancer1R01CA299862-01 | GUO, CHUN-JUN | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $606,839 | CPSS |
| 2025 | Role of bacterial-derived small molecules in immunotherapy1R01CA292532-01A1 | JOBIN, CHRISTIAN | UNIVERSITY OF FLORIDA, FL | $540,288 | TIO |
| 2025 | Exploiting immunostimulatory microbial pattern recognition to improve head and neck cancer therapy1R01DE033686-01A1 | WANG, XIANG-YANG SHAWN | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $427,208 | TIO |
| 2024 | Targeting tumoral Lactobacillus iners to improve outcomes in cervical cancers1R37CA285794-01A1 | COLBERT, LAUREN ELIZABETH | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $660,742 | TIO |
| 2024 | Genetically-engineered Bacteria Overcome Therapy Resistance1R01CA292860-01 | MIMEE, MARKWEICHSELBAUM, RALPH R | UNIVERSITY OF CHICAGO, IL | $581,087 | TIO |
| 2024 | The role of the mycobiome in cancer1R01CA286920-01 | ILIEV, ILIYAN DIMITROV | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $508,693 | CPSS |
| 2024 | Reversing cancer immunosuppression using attenuated Listeria monocytogenes1R01CA283604-01A1 | DUPAGE, MICHELPORTNOY, DANIEL A | UNIVERSITY OF CALIFORNIA BERKELEY, CA | $473,641 | TIR |
| 2023 | Metabolism of cancer chemotherapeutics by the human gut microbiome1R01CA255116-01A1 | TURNBAUGH, PETER JAMES | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $603,222 | CPSS |
| 2023 | Hypoxia-activated probiotic agents for breast cancer1R01CA272564-01A1 | YAMADA, TOHRU | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | $380,760 | ZRG1 |
| 2023 | Employing Humanized Microbiome Mice to Understand Immune Activation and Translational Therapeutic Potential in Glioblastoma1R01CA270750-01A1 | MCFARLAND, BRADEN COX | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $329,317 | CPSS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.